GGrantIndex
← Leaderboards

Michael H Tomasson

University Of Iowa

$7,217,496
Attributed
$8,001,265
Total exposure
8
Grants
7
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $693.9K · FY200625
$1M$750K$500K$250K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$8,001,265 · 8

By mechanism

R01$4,894,669 · 3
P01$1,723,265 · 1
R21$900,971 · 3
K08$482,360 · 1

Top collaborators

Most similar at University Of Iowa

Same institution · by research overlap

Others in their field

Top investigators on “Cells

Research focus

CellsSamplingGenesMultiple MyelomaMalignant NeoplasmsResearch StudyTumorCell LineResistanceMutantOncogenesBone MarrowTransplantationChemotherapyPathogenesisProteinsDiagnosisAntibodiesChromosomal TranslocationPhenotypePlasmaB-LymphocytesMutationAffect

Grant awards (28)

Sleep Disordered Breathing as a Targetable Risk Factor in Multiple Myeloma$584,230
R01 · FY2025 · CA · contact PI
Sleep Disordered Breathing as a Targetable Risk Factor in Multiple Myeloma$555,020
R01 · FY2024 · CA · contact PI
Sleep Disordered Breathing as a Targetable Risk Factor in Multiple Myeloma$572,544
R01 · FY2023 · CA · contact PI
MOLECULAR TARGETS OF TRANSLOCATION T(4;14) IN MULTIPLE MYELOMA PATHOGENESIS$344,025
R01 · FY2018 · CA · contact PI
ROLE OF ACA11, AN ORPHAN SMALL NUCLEOLAR RNA IN RESISTANCE TO CANCER CHEMOTHERAPY$315,400
R01 · FY2017 · CA · contact PI
MOLECULAR TARGETS OF TRANSLOCATION T(4;14) IN MULTIPLE MYELOMA PATHOGENESIS$309,622
R01 · FY2017 · CA · contact PI
MOLECULAR TARGETS OF TRANSLOCATION T(4;14) IN MULTIPLE MYELOMA PATHOGENESIS$316,230
R01 · FY2016 · CA · contact PI
ROLE OF ACA11, AN ORPHAN SMALL NUCLEOLAR RNA IN RESISTANCE TO CANCER CHEMOTHERAPY$181,640
R01 · FY2016 · CA · contact PI
ROLE OF ACA11, AN ORPHAN SMALL NUCLEOLAR RNA IN RESISTANCE TO CANCER CHEMOTHERAPY$133,760
R01 · FY2016 · CA · contact PI
MOLECULAR TARGETS OF TRANSLOCATION T(4;14) IN MULTIPLE MYELOMA PATHOGENESIS$316,230
R01 · FY2015 · CA · contact PI
ROLE OF ACA11, AN ORPHAN SMALL NUCLEOLAR RNA IN RESISTANCE TO CANCER CHEMOTHERAPY$315,400
R01 · FY2015 · CA · contact PI
MOLECULAR TARGETS OF TRANSLOCATION T(4;14) IN MULTIPLE MYELOMA PATHOGENESIS$329,230
R01 · FY2014 · CA · contact PI
ROLE OF ACA11, AN ORPHAN SMALL NUCLEOLAR RNA IN RESISTANCE TO CANCER CHEMOTHERAPY$305,938
R01 · FY2014 · CA · contact PI
ROLE OF ACA11, AN ORPHAN SMALL NUCLEOLAR RNA IN RESISTANCE TO CANCER CHEMOTHERAPY$315,400
R01 · FY2013 · CA · contact PI
Genomics of AML: Contribution of Cytokine Signaling Pathways to Leukemogenesis$332,007
P01 · FY2012 · CA · contact PI
ENVIRONMENT & GENETICS OF MONOCLONAL GAMMOPATHY OF UNCERTAIN SIGNIFICANCE (MGUS)$197,489
R21 · FY2012 · AG · contact PI
Genomics of AML: Contribution of Cytokine Signaling Pathways to Leukemogenesis$527,901
P01 · FY2011 · CA · contact PI
ENVIRONMENT & GENETICS OF MONOCLONAL GAMMOPATHY OF UNCERTAIN SIGNIFICANCE (MGUS)$165,972
R21 · FY2011 · AG · contact PI
Genomics of AML: Contribution of Cytokine Signaling Pathways to Leukemogenesis$293,857
P01 · FY2010 · CA · contact PI
EXPLORATION OF NEUROBEACHIN (NBEA)'S ROLE IN MULTIPLE MYELOMA$165,300
R21 · FY2010 · CA · contact PI
Genomics of AML: Contribution of Cytokine Signaling Pathways to Leukemogenesis$288,079
P01 · FY2009 · CA · contact PI
EXPLORATION OF NEUROBEACHIN (NBEA)'S ROLE IN MULTIPLE MYELOMA$198,360
R21 · FY2009 · CA · contact PI
Genomics of AML: Contribution of Cytokine Signaling Pathways to Leukemogenesis$281,421
P01 · FY2008 · CA · contact PI
Genetic Progression Factors in Multiple Myeloma and MGUS$173,850
R21 · FY2006 · CA · contact PI
MOLECULAR ANALYSIS OF TRANSFORMATION IN TEL/PDGFR MICE$120,590
K08 · FY2003 · CA
MOLECULAR ANALYSIS OF TRANSFORMATION IN TEL/PDGFR MICE$120,590
K08 · FY2002 · CA
MOLECULAR ANALYSIS OF TRANSFORMATION IN TEL/PDGFR MICE$120,590
K08 · FY2001 · CA
MOLECULAR ANALYSIS OF TRANSFORMATION IN TEL/PDGFR MICE$120,590
K08 · FY2000 · CA